Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas

被引:19
|
作者
Mete, Ozgur [1 ,2 ,3 ]
Pakbaz, Sara [1 ,2 ]
Lerario, Antonio M. [4 ]
Giordano, Thomas J. [4 ,5 ]
Asa, Sylvia L. [6 ,7 ]
机构
[1] Univ Hlth Network, Dept Pathol, 200 Elizabeth St,11th Floor, Toronto, ON M5G 2C4, Canada
[2] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[3] Princess Margaret Canc Ctr, Endocrine Oncol Site, Toronto, ON, Canada
[4] Univ Michigan, Dept Internal Med, Div Metab Endocrinol & Diabet, Ann Arbor, MI USA
[5] Univ Michigan, Dept Pathol, Ann Arbor, MI USA
[6] Case Western Reserve Univ, Dept Pathol, Univ Hosp Cleveland, Med Ctr, Cleveland, OH USA
[7] Case Western Reserve Univ, Cleveland, OH USA
关键词
alpha-inhibin; VHL; SDHB; paraganglioma; pheochromocytoma; IMMUNOHISTOCHEMICAL MARKERS; MEDULLARY TUMORS; SDH MUTATIONS; SUBUNIT; PHENOTYPE; PATHWAY; MELAN;
D O I
10.1097/PAS.0000000000001715
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Alpha-inhibin expression has been reported in pheochromocytomas and paragangliomas (PPGLs). We analyzed alpha-inhibin immunohistochemistry in 77 PPGLs (37 pheochromocytomas [PCCs] and 40 paragangliomas) and correlated the results with catecholamine profile, tumor size, Ki-67 labeling index, succinate dehydrogenase B subunit and carbonic anhydrase IX (CAIX) staining, and genetic pathogenesis. PPGLs were classified as pseudohypoxic cluster 1 disease with documented VHL mutation or SDHx mutation or biochemical phenotype, whereas NF1-driven and RET-driven PPGLs and those with a mature secretory (adrenergic or mixed adrenergic and noradrenergic) phenotype were classified as cluster 2 disease. The Cancer Genome Atlas data on INHA expression in PPGLs was examined. Alpha-inhibin was positive in 43 PPGLs (56%). Ki-67 labeling indices were 8.07% and 4.43% in inhibin-positive and inhibin-negative PPGLs, respectively (P<0.05). Alpha-inhibin expression did not correlate with tumor size. Alpha-inhibin was expressed in 92% of SDHx-related and 86% of VHL-related PPGLs. CAIX membranous staining was found in 8 of 51 (16%) tumors, including 1 SDHx-related PCC and all 5 VHL-related PCCs. NF1-driven and RET-driven PPGLs were negative for alpha-inhibin and CAIX. Alpha-inhibin was expressed in 77% of PPGLs with a pseudohypoxia signature, and 20% of PPGLs without a pseudohypoxia signature (P<0.05). PPGLs with a mature secretory phenotype were negative for CAIX. The Cancer Genome Atlas data confirmed higher expression of INHA in cluster 1 than in cluster 2 PPGLs. This study identifies alpha-inhibin as a highly sensitive (90.3%) marker for SDHx/VHL-driven pseudohypoxic PPGLs. Although CAIX has low sensitivity, it is the most specific biomarker of VHL-related pathogenesis. While alpha-inhibin cannot replace succinate dehydrogenase B subunit immunohistochemistry for detection of SDHx-related disease, it adds value in prediction of cluster 1 disease. Importantly, these data emphasize that alpha-inhibin is not a specific marker of adrenal cortical differentiation, as it is also expressed in PCCs.
引用
收藏
页码:1264 / 1273
页数:10
相关论文
共 50 条
  • [1] LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas
    Li, Huihua
    Hardin, Heather
    Zaeem, Misbah
    Huang, Wei
    Hu, Rong
    Lloyd, Ricardo, V
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2021, 55
  • [2] Alpha-inhibin expression in canine ovarian neoplasms:: Preliminary results
    Marino, G
    Nicòtina, PA
    Catone, G
    Bontempo, RA
    Zanghì, A
    VETERINARY RESEARCH COMMUNICATIONS, 2003, 27 (Suppl 1) : 237 - 240
  • [3] Diagnosis of Pheochromocytomas and Paragangliomas
    Castinetti, F.
    Barlier, A.
    Sebag, F.
    Taieb, D.
    ONCOLOGIE, 2019, 21 (5-12) : 105 - 111
  • [4] Hypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas
    Amorim-Pires, Diana
    Peixoto, Joana
    Lima, Jorge
    CYTOGENETIC AND GENOME RESEARCH, 2016, 150 (3-4) : 227 - 241
  • [5] Familial pheochromocytomas and paragangliomas
    King, Kathryn S.
    Pacak, Karel
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2014, 386 (1-2) : 92 - 100
  • [6] Screening for Pheochromocytomas and Paragangliomas
    Eisenhofer, Graeme
    CURRENT HYPERTENSION REPORTS, 2012, 14 (02) : 130 - 137
  • [7] Pheochromocytomas and paragangliomas
    Yen, Kevin
    Lodish, Maya
    CURRENT OPINION IN PEDIATRICS, 2021, 33 (04) : 430 - 435
  • [8] Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
    Mete, Ozgur
    Asa, Sylvia L.
    Gill, Anthony J.
    Kimura, Noriko
    de Krijger, Ronald R.
    Tischler, Arthur
    ENDOCRINE PATHOLOGY, 2022, 33 (01) : 90 - 114
  • [9] Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas
    Ozgur Mete
    Sylvia L. Asa
    Anthony J. Gill
    Noriko Kimura
    Ronald R. de Krijger
    Arthur Tischler
    Endocrine Pathology, 2022, 33 : 90 - 114
  • [10] Stathmin Expression in Pheochromocytomas, Paragangliomas, and in other Endocrine Tumors
    Peter M. Sadow
    Kandelaria M. Rumilla
    Lori A. Erickson
    Ricardo V. Lloyd
    Endocrine Pathology, 2008, 19 : 97 - 103